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MICRODIALYSIS, MICROPERFUSION, AND CONVECTION CURRENT-




Glioblastoma multiforme (Glioma) is an extremely aggressive tumor that arises from 
intrinsic glial cells in the central nervous system (CNS)5. It is the most common primary 
brain tumor in humans and has a typical survival time of 15-16 months5. Current 
treatments for gliomas include surgery, radiation, and treatment with temozolomide 
(TMZ). While these treatments tend to add 2-3 months to a patient’s survival, none have 
been capable of altering the course of the disease1.  
 
One of the shortcomings of novel therapeutics for glioma, is the inability to evaluate in 
real time how therapeutics are affecting the patient. There is also the problem of the 
blood brain barrier (BBB), which can be overcome by administering drugs through an 
intracranial catheter (delivered via CED). The primary obstacle that’s been observed in 
intracranial drug delivery is the inadequacy of the delivery. This inadequacy is an 
inability of the drug to diffuse homogenously throughout the tumor. CED also creates a 
possibility for toxicity due to highly concentrated volumes of drugs delivered; we believe 
the novel delivery method we are trying to develop, will make this possibility null.  
 
The purpose of this study was initially to demonstrate the problem of delivering drugs via 
diffusion while simultaneously collecting biomarkers to interpret efficacy of the drugs, 
 vi 
due to differing molecular weights. The other objective of this study was to demonstrate 
that it is possible to manipulate both the direction of bulk flow and the rate of diffusion of 
drugs delivered through a catheter using a gel phantom as a representative of brain tissue.  
What we found is that by utilizing a two-catheter method with convection and retro-
convection enhanced delivery, we could in fact manipulate these parameters and achieve 
a more even distribution of drug (represented by fluorophores in our experiments). Using 
these two catheter methods, we will also be able to collect fluids from the tumor to 
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Glioblastoma (glioma) is an aggressive neoplastic disease that arises from glial cells in 
the brain or spinal cord. The survival curve for this disease has increased very little since 
the cancer was first characterized in the 1800s. Since its discovery, it has plagued nations 
with its grim prognosis and dim prospects of novel interventions. It is the most common 
primary brain tumor, accountable for 52% of all primary brain tumors5. The typical age 
of someone diagnosed with glioma is 64 and it tends to have some preference for males5. 
This cancer is plagued with challenges to researchers and physicians through its 
uncommon physiological and biochemical barriers5. These barriers include things such 
as: metabolism, flux, and the blood brain barrier.  
 
Drugs administered to treat gliomas (i.e. TMZ) are capable of diffusing across the BBB 
but are unspecific and create undesirable systemic effects. TMZ is currently the only 
chemotherapeutic available for treatment of gliomas. It is DNA alkylating agent that is 
capable of methylating both guanine and adenine regions preferentially9. This 
methylation leads to an arresting of the cell cycle, ultimately causing cell death9. This is 
not a unique mechanism of action for chemotherapeutics; however, it is unique in its 
ability to freely diffuse across the BBB. Another effect of TMZ is that even if it doesn’t 
directly cause cell death, it typically enhances the effect of radiation therapy9. TMZ is 
known, as many chemotherapies are, to cause some negative side effects in the patient. 
These side effects include, but are not limited to: immunocompromise, nausea, amnesia, 
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convulsions, fever, muscle weakness, blood in urine, back pain, etc10. The extent to 
which these side effects are experienced varies patient-to-patient. The heterozygous 
nature of tumors makes it impossible to eradicate gliomas with just a single 
chemotherapeutic. Research has shown that there exist many glioma cell lines which are 
completely resistant to treatment with TMZ11. Often times, these resistant cell lines do 
not make up a majority of the tumor before treatment, and remain inactive for some time. 
Cell lines of this nature are termed senescent cells. Senescent cells play a large role in 
making it impossible to eradicate a recurrent glioma11. 
 
While other more targeted interventions for gliomas, such as surgical resection and 
radiation, seem to spare the patient at least a couple of months if caught early and used in 
conjunction with TMZ, they are insufficient in providing any sort of long-term treatment. 
Surgical resection manages to remove a large portion of the cancerous mass while 
radiation tends to target the marginal cancer for complete eradication. TMZ is also 
introduced in an attempt to completely rid the patient of any remaining glioma cells. One 
major reason for the lack of efficacy from TMZ aside from cell senescence is due to the 
late diagnosis often received for gliomas. On average, by the time a glioma is diagnosed, 
there are already roughly 3-6X1010 cells present2. For TMZ and your immune system to 
have a measurable effect against gliomas, the number of cells has to be reduced to about 
105 cells, something that is typically not achieved through resection or radiation2. The 
limitation on detection of early gliomas is two-fold: 1, it is difficult to detect tumors 
smaller than 3-6X1010 cells using MRI and 2, patients often don’t start exhibiting 
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symptoms long before this stage2. Unfortunately, there is currently no standard screening 
process for individuals who are at risk for developing gliomas. As a result of the failure 
of early glioma detection, we are forced to rely on therapeutics. The problem with relying 
on therapeutics is that we only have one chemotherapy drug that is approved for 
treatment of gliomas. Due to the limitations of TMZ after surgery and radiation, there is a 
huge demand for more effective therapeutics. This is the basis of the dilemma faced by 
glioma researchers searching for new therapeutics. There is a demand for new 
development, yet there’s a lack of ability to determine the efficacy in real time. 
 
In 1994, a new method for drug delivery into the brain and tumor was developed at the 
national institute of health7. This new method was termed convection enhanced delivery 
(CED). The purpose of this new delivery method was to bypass the BBB completely, and 
deliver drugs directly into the tumor via a convective flow. This novel method not only 
allowed for a bypassing of the BBB, but due to the influx of fluid through the catheter, it 
created a positive pressure gradient for the drug, allowing for more rapid flow throughout 
the tumor. To place a CED catheter into a patient’s brain or tumor, a minor surgery is 
performed to allow for placement of the guide cannula and catheter.  
 
The catheter is typically just a cylinder with a hole at the end, but micro-perfusion 
catheters can be used as well. The benefit of using a micro-perfusion catheter instead of 
performing open flow CED, is the catheter will prevent the uptake of any large proteins 
or cells, thus helping prevent any clogging of the machinery. The catheter then has fluid 
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pumped into it at a slow rate, creating a positive pressure and allowing the perfusate to 
flow throughout the tumor. The opposite of this can also be done to pull drugs out of 
capillaries, this is known as retro convection enhanced delivery (rCED). The idea behind 
rCED is instead of creating a positive pressure gradient, you will create a negative 
pressure gradient. This negative pressure gradient will create a larger driving force for 
molecules to move out of capillaries. While utilizing rCED, it is more common to use a 
micro-perfusion catheter to prevent the uptake of any large matter. This also works by 
placing a small catheter into the brain, but instead of pushing fluid in, you place a pull 
pump on the catheter to create a negative pressure gradient and collect fluid. The CED 
system was truly a breakthrough; however, it comes with its limitations.  
 
One of the limitations of CED, is that you cannot use it to collect ECF as you can with 
micro-dialysis. The micro-dialysis catheter is placed just as a CED catheter would be; 
however, it does not create a positive pressure gradient. The micro-dialysis catheter 
dialyzes molecules in and out of the catheter based on their concentration gradient and 
whether or not they are small enough to pass through the membrane. The benefit of the 
micro-dialysis system is that it allows for semi-selective collection of extra cellular fluid 
(ECF) from the tumor (collection is the primary function of this catheter). Being able to 
collect dialysate from a tumor is beneficial because it may theoretically be used to help 
characterize the glioma as well as determine how its responding to a therapy based on its 
metabolic signature. Another potential problem that arises from CED, is the possibility 
for toxicity. As drugs are being pumped into a tumor through a CED catheter, they will 
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start diffusing down their concentration and pressure gradients; however, the rate at 
which they clear may not be fast enough to prevent concentrations that are toxic. 
 
The micro-dialysis catheter, however, is not effective in dialyzing solutes out into the 
brain, a process known as reverse micro-dialysis. Delivering drugs through a micro-
dialysis catheter relies solely on the concentration of the drug inside and outside of the 
catheter whereas CED using both a concentration gradient and a pressure gradient. The 
problem with this is that once the drug reaches equilibrium (the point at which 
concentration inside catheter equals concentration outside), much of the drug will not be 
dialyzed across the catheter. Any drug that is not dialyzing across the catheter is being 
lost. This creates a few problems: 1-The drug is only diffusing down its concentration 
gradient and not with the assistance of a pressure gradient, meaning it will take longer for 
it to reach peripheral parts of the tumor 2-Because it is diffusing only by the power of 
diffusion, the concentration gradient is very steep and therefore there is not an even 
distribution 3-it becomes more complicated to determine dosage when x amount of drug 
is being lost.  
 
Micro-dialysis catheters also have specific cut-offs for the size of molecules that they 
allow to dialyze. This is beneficial when trying to collect ECF; however, trying to dialyze 
a drug out of the catheter will be made more difficult by this. Even if the catheters cut-off 
is larger than the size of the drug of interest, dialyzing of that drug will still be less 




We hypothesized the solution to the problems presented by both CED and reverse micro-
dialysis, is the marriage between CED and rCED used in concert. By matching flow out 
through a CED catheter to flow in through a parallel rCED catheter, we hoped to 
demonstrate that we can manipulate multiple variables including the path of drug 
disbursement and the rate of diffusion. By having a parallel rCED catheter, we could also 
allow for the collection of ECF material to be analyzed. While rCED is typically only 
used as a way to aid drugs in crossing the BBB, there is no reason why the fluid collected 
by it can’t be used for analysis2.  It is especially important to use a micro-perfusion 
catheter with rCED collection to prevent the uptake of any cells or large proteins.   
 
In order to demonstrate our ability to do these things, we used a gel phantom to represent 
brain tissue. Earlier studies had been done in search of developing an adequate model for 
brain tissue1,3. This model lacked some physiological barriers, such a flux and 
metabolism, observed in the brain, but ii served as an idealized vehicle to demonstrate 
our early findings in. By using a 0.6% agarose gel, we closely mimicked the brains 
propensity to allow for diffusion of molecules1. To represent our drugs and metabolites, 
we used various fluorophores with similar molecular weights to the molecules of interest. 
These fluorophores included: Alexafluor 488A Amine, Alexafluor 488A Hydrazide, and 
7-Amino-4-Methylcoumarin. They were used to represent D2-hydroxygluturate, 
temozolomide, NAMPT inhibitors, and NAD+. Fluorophores were pumped into the 
phantom using a syringe pump, and pulled out using a roller pump. Manipulating these 
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two pumps independently is what allowed us to control how the fluorophores diffused 
throughout the phantom. The results obtained illustrate the theoretical manipulation we 

















































Fig. 1. Distribution of  Drug in Reverse Micro-Dialysis vs. Convection and  
retro-Convection Enhanced Delivery: A schematic illustration of the 
theoretical distribution of drugs introduced into tumor through reverse micro-
perfusion or reverse micro-dialysis and CED paired with rCED. (A) 
illustrates the theoretical distribution of drugs into the brain using reverse 
micro-dialysis. This same model could also be applied to the distribution in 
the brain using reverse micro-perfusion. The dialysis character of this system 
is not depicted in the image (B) illustrates the theoretical distribution of drugs 
utilizing a two-catheter CED and rCED system.  
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• Create a model for illustrating diffusion in the brain  
• Test the comparative diffusion characteristics of fluorophores of varying sizes to 
represent drugs diffusion  
• Determine micro-dialysis equilibrium point (point at which the concentration of 
fluorophore outside catheter matches concentration inside catheter 
• Establish whether or not paired CED/rCED  can promote a more even distribution 


















Brain Tissue Phantom Preparation: 
Multiple studies have been done in search of finding an idealized gel phantom to 
represent the brain1,3. The gel model seemed best be suited for our work, as this would 
allow for fast replication of experiments and yield the ability to control the environment. 
Utilizing a gel model would also yield us the ability to easily perform imaging on our 
experiments. Studies published by Zhi-Jian Chen M.D., PhD. set the predicate for work 
in gels1. What Dr. Jian found was that 0.6% agarose gel is well suited for representing 
brain matter, this is due to the diffusion characteristics that he observed in the gel1. Dr. 
Jian made this determination by conducting parallel experiments with pig brains and gels, 
in which he used diffusion rate, volume, and pressure at the end of the catheter as metrics 
for determining an adequate gel phantom1. After comparing gels made from varying 
agarose concentrations, Dr. Chen concluded that a 0.6% agarose gel was an ideal model 
as it had almost identical results for the metrics measured when compared to the pig 
brain1.  
 
To prepare our gels, we first had to prepare the petri dishes. Every dish received two 
1mm holes drilled 5mm apart. This distance was chosen as it is our standard distance 
between probes that our lab inserts into rate brain. We hoped to demonstrate that even at 
this distance, flow could be manipulated. These holes were drilled to later accommodate 
both the micro-dialysis and the micro-perfusion catheters (the catheter type we used for 
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CED and rCED). Parafilm was then wrapped around the edges of the dish to prevent any 
leakage from the holes when adding the agarose solution.  
 
While preparing the agarose solution,  the first step is to dilute a 50X stock concentration 
of TAE (ThermoFisher Scientific, catalog #409) to a 1X concentration. 100 mL of the 1X 
solution was then mixed with .6g of ultrapure agarose (ThermoFisher Scientific, catalog 
#16500100). The solution was mixed in a 200 mL Erlenmeyer flask and intermittently 
heated to allow for the agarose to dissolve completely. After fully homogenizing the 
solution, it was added to ten 35X10 mm petri dishes (these dishes have an internal 
volume of 10 mL). After allowing the gels to solidify, those that weren’t being used the 
same day were wrapped completely in parafilm and refrigerated at 4oC.  
 
Gels that were not used the same day had the dates written on them. No pre-made plates 
were used after 7 days. Waiting longer than 7 days could potentially allow for drying of 
































Utilizing a gel model would also 
yield us the ability to easily 
.  5 mm 
CED rCED 
5 mm 
Fig. 3. This figure is a schematic of how each petri dish used in the subsequent 
experiments was set-up. The 1 mm holes drilled for catheter placement were 
oversized to allow for slight manipulation of catheter placement once placed, in order 
to ensure that the distance was exactly 5 mm for each experiment. The schematic 
depicts the relative positioning of the CED and rCED catheters. While running single 
catheter experiments (i.e. micro-dialysis experiments) the catheter was placed in the 
hole on the left and the hole on the right side remained covered with parafilm. 
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Comparative Diffusion of Fluorophore Using Reverse Micro-Dialysis  
One of the theoretical issues with trying to collect metabolites for tumor characterization, 
while simultaneously dialyzing drugs into the tumor, was the mismatch in diffusion rates 
between drug and metabolite. If the metabolite of interest is diffusing at a faster rate than 
the drug being tested, the actual effects of the drug may not be well represented by the 
metabolite being collected . This experiment was conducted for the sole purpose of 
demonstrating that in a brain model, there will still be a discrepancy between the 
diffusion rates of different sized molecules.  
 
In order to do this, instruments including: the syringe pump (New Era Pump model NE-
1200), digital microscope (Keyence model BZX-810), and temperature regulator (Tokai 
Hit model INU-KIW-F1), had to be set-up. For the roller pump, it must first be confirmed 
that it is calibrated. This is done by running distilled water through the syringe the pump 
has been set for, collecting a certain volume based of the pump rate, and weighing to 
confirm that it has pumped the correct volume. The flow rate of the pump is then set to 1 
µL per minute for the experiment. The temperature regulator is then attached to the 
microscope’s slide (this allows for maintaining the gel at 37oC to better mimic actual 
brain matter, throughout the duration of the experiment). Finally, the digital microscope 





We then created 60 µm solutions of the following: 7-Amino-5-Methylcoumarin (Sigma-
Aldrich, Catalog: 26093-31-2, MW ~175 Daltons), Alexa Fluor 488A Amine (Sigma-
Aldrich, Catalog: SCJ4600014, MW ~597 Daltons), and Alexa Fluor 488A Hydrazide 
(Sigma-Aldrich, Catalog: SCJ4600015, MW ~928 Daltons). These fluorophores were 
chosen due to their similar size to some of our drugs and metabolites of interest, as well 
as for their photosatbility8. The drugs and metabolites we hoped to represent with these 
fluorophores include: D2-hydroxygluturate (MW ~148 Daltons), TMZ (MW ~194 
Daltons), and NAD+ (MW~663 Daltons). 150 µL of fluorophore solution was added to a 
1 mL syringe that the pump is specifically calibrated for. Pump calibration is based off of 
the internal diameter of the syringe being used, 200 µL Hamilton syringes is what we 
used for all experiments. Dialysis tubing (PES) was run from the end of the syringe, to 
the inlet of a 20 KD micro-dialysis catheter (CMA 8011202), and another piece from the 
outlet of the catheter. This catheter was then placed into the gel through the hole 
previously drilled into the dish. The catheter was secured by gluing the guide cannula to 
the petri dish using dental cement, ensuring no travel of the catheter as the scope’s slide 
moved around. Images were captured every 10 minutes over a period of 80 minutes. This 
process was replicated three times for each fluorophore. The images were later analyzed 














Set-up of the 
micro-dialysis in 
phantom gel 
system. Two gels 
were run 
simultaneously to 
allow for fast 
replication. The 
chamber that the 




keep it at 37oC.  
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Measuring Loss in the Micro-Dialysis System  
This test was performed to determine if there was any loss of fluorophore through the 
tubing and at what time equilibrium was reached inside of the catheter. Making these 
determinations would help us to demonstrate one of the major pitfalls of using micro-
dialysis for introducing a drug into the brain.  
 
Equilibrium in this experiment, is defined as the point at which the concentration of 
trypan blue inside the catheter, equals the concentration of trypan blue outside of the 
catheter. Determination of this is possible by analyzing the dialysate from the system, and 
measuring its absorbance values. When the absorbance plateaus, we know the 
equilibrium has been reached. The experiment was conducted by running trypan blue 
through the 20 KD catheter into a gel, and collecting the dialysate throughout the 
experiment at every 10-minute timepoint for 80 minutes. The dialysate, which was 
collected into a 384 well transparent plate, was then analyzed under a Tecan Spark plate 
reader to determine the relative absorbance in each well. It was important for us to 
determine loss and equilibrium point by the system, because this would give us some 


















Fig. 6- Tecan Spark plate reader 
used for all absorbance 
measurements, fluorescence 
measurements were conducted in a 







Push Pull (CED and rCED) to Manipulate Fluorophore Movement  
To determine if the movement of drugs in the brain can be manipulated, this test utilizing 
a two-catheter, push-pull system was performed. This experiment was used to 
demonstrate if the impact of molecular size in diffusion can be nullified through this 
system. We focused primarily on the implication of molecular weight to diffusion rate, as 
this would allow us to build an application for any drug of metabolite. We believed that if 
our fluorophores where introduced into an identical environment, the largest factor 
contributing to their ability to diffuse would be size.  
 
The experiment was performed in the same phantom gel and ambient conditions as the 
previous experiment, but with two perfusion catheters. Catheter 1 was the CED catheter, 
it pushes fluid into the media but does not pull any out. Catheter 1 was controlled by the 
same push pump used in the previous experiment. Catheter 2 is the rCED catheter, it 
pulls fluid out of the media but does not push any in. Catheter 2 is controlled by a roller 
pump (EjCOM ERP-10). The catheters were placed 5mm apart for each experiment and 
were run at variable speeds. Throughout the three sets of experiments, the inflow and 
outflow rates were varied independently. We believed that by varying our flow rates and 
creating both positive and negative pressure areas in the phantom, we could pattern the 
fluorophore movement to fit our needs. This is something we hoped to magnify by 




Images for these experiments were captured every 10 minutes and utilized stitched 
imaging to expand the image area. The exposure was also adjusted to 1/2000sec. to avoid 
overexposure, which was observed in the previous experiment comparing diffusion rates 
of fluorophores. Images were analyzed in the Keyence software, where we measured the 
fluorescent intensity across a horizontal line. Distance from the left edge of the image to 
the CED catheter was also measured, this point became our zero point for graphs 
generated from these experiments.  
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Fig.7-Image depicting placement of CED and rCED 
catheter in gel phantom. CED catheter is located left side 
of image, rCED catheter is located right side of image. 
These catheters have been placed 5 mm apart which is the 
























Fig. 8-Details the process of measuring fluorescence from a sample as was done in 







Comparative Diffusion Rates 
Testing the hypothesis that fluorophores would diffuse in a phantom gel according to 
their molecular weight, the results were the smallest fluorophore (7-Amino-5-
Methylcoumarin) diffused across the gel the fastest, 488A Amine diffusing at the second 
highest rate and 488A Hydrazide diffusing the slowest. The images captured were 
processed using the hybrid cell count function on the Keyence software. This allowed for 
clearly defined borders and gave a distinct, replicable cut-off for the fluorescence. After 
processing the images, each image was measured from the origin (catheter) to the edge of 
the fluorescent cut-off. Images were measured along an X and a Y axis and then 
averaged.  
 
This experiment also demonstrated to us that there is a problem to overcome if we wish 
to measure the effect of drugs we administer in real time. What this model shows is that if 
we tried to administer a drug that is larger than the marker we’re collecting through the 
micro-dialysis catheter, there’s a possibility that what we will be sampling won’t be 
indicative of the immediate surrounding tissues affected by the drug, but rather reflect the 
peripheral tissues unaffected by the drug. This creates a large problem because if this is 
indeed the case, then by utilizing this method in vivo we may not know how a tumor is 








Fig.9. For each of the replicates above, the top row is the 7-Amino-5-
Methylcoumarin, the second row is the 488A Amine, and the third row is the 
488A Hydrazide. These images were captured at an exposure of 1/300Sec. 
and were further processed using a hybrid cell counter to define the 
perimeters so clearly.  











































Table 1. a) Comparative diffusion distances of three fluorophores. This graph 
was developed from three replicates of each fluorophore and analysis was 
conducted on it using the GraphPad software. b) One-Way Anova analysis of the 
three fluorophores. The P value indicates that the diffusion distances of these 




Table 2. Measurement of the fluorescent intensity of the three fluorophores 
used in the experiment at 20, 40, and 60 minutes. Images became 
oversaturated at an intensity of 250. 
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Table 2. Measurement of the fluorescent intensity of the three fluorophores 
used in the experiment at 20, 40, and 60 minutes. Images beca e 
oversaturate at an intensity of 25 . 



























































Measuring Loss in Micro-dialysis System  
After completing this experiment, two things were able to be confirmed with relative 
certainty: 1-The catheter in the gel reaches equilibrium almost immediately 2-There 
doesn’t appear to be any measurable loss of trypan blue in the tubing (i.e. trypan blue 
sticking to the tubing). This was determined based off of the absorbance of the trypan 
blue collected throughout the experiment, which remained the same from beginning to 
end. 
 The most important information we received from this experiment was the almost 
immediate equilibration. This result implicates a couple of truths about the reverse micro-
dialysis system. Through this experiment we are able to see just how ineffective this 
system is at delivering drugs into the brain. Immediate equilibration means that we would 
be losing administered drug through the system almost immediately. As it was mentioned 
earlier, this would make for very difficult dosage calculating in addition to the system 
just being inefficient and wasteful. 
While we didn’t see any trypan blue sticking to the tubing, this is not indicative of how 








Push Pull (CED and rCED) to Manipulate Fluorophore Movement  
With the previous experiments established, we were then able to test if by using one 
catheter to introduce fluid into the media (CED), and another catheter to remove fluid 
from the media (rCED), we could control the net movement of the fluid infused and also 
accelerate its diffusion rate. What was found is that it was possible to alter the net 
movement by using varying rates of rCED, we were able to pull the fluorophore from the 
CED catheter to the rCED catheter. Introducing a negative pressure acted as a guide for 
the fluorophore under positive pressure. The peak fluorescent intensity was also reduced, 
so it is believed that the diffusion rate was increased, but further testing is required to 
confirm. The following graphs depict the extent to which we were able to manipulate the 
fluorophores movement. 
Table 3. This table shows the absorbance measurements for trypan blue 
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Left of Catheter 




Distribution of Fluorophore in CED with rCED
























Distribution of Fluorophore in CED with rCED
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Fig. 10. This figure illustrates the amount of influence the two-catheter system has 
at varying rates of speed. Time zero shows some measurement in graphs due to 
passive diffusion out of catheter tips before the experiment began. a) This graph is 
generated from the experiment in which the CED and rCED catheters had 
matching flow rates (both 1 µL per minute). b) This graph is generated from the 
experiment in which CED had a flow rate of 1 µL per minute, and rCED had a 
flow rate of 2 µL per minute. c) this graph is generated from the experiment in 

































































Table 4. The above graph illustrated the net increase in movement 
of fluorophore to the side with the rCED catheter, as compared to 
the contralateral side. The data illustrates that by matching the flow 
rates, there is only a slight flux toward the rCED catheter; however, 
simply doubling the rCED flow causes a much larger net flux. 
Table 5. This graph 
illustrates the 
comparative peak 
fluorescent intensity of 
the three CED/rCED 
experiments. The graph 
shows that at higher 
rCED flow rates, the peak 
concentration is 
decreasing. This is a 
beneficial finding as it 
suggests that this may be 
used to avoid inducing 




The purpose of the earlier experiments was to demonstrate that there was in fact a 
shortcoming pertaining to passive diffusion in the brain if one hopes to deliver drugs this 
way. That shortcoming was visualized using fluorophores of varying sizes that were run 
through a gel phantom to demonstrate their differing propensities to diffuse throughout 
brain tissue. The catheter used for these experiments was a CMA 20 KD catheter and the 
flow rate was set to 1µL/min. for each set of experiments. What was found was that the 
smaller fluorophores diffused at a greater rate than the larger ones. This was an expected 
result; however, we believed it to be of importance to demonstrate in the gel phantom. 
The fluorescent intensity vs. distance was measured from the images captured in this 
experiment, and it was found that the exposure of 1/300sec. was too high (the images 
were overexposed). The overexposure wasn’t caught right away because when the 
experiments were set up, the initial exposure was set based off being able to see the end 
of the catheter in the gel. Because the catheter only had a small amount of fluorophore in 
it, the exposure had to be set relatively high to visualize. As the experiments ran, the 
fluorophore built up around the catheter and became too concentrated for the exposure 
time that was set. This set the predicate for lowering the exposure to 1/2000sec. in later 
experiments. Exposures of 1/500, 1/1000, and 1/1500 were all tested before deciding to 
use 1/2000sec. The differing diffusion rates observed in this experiment have potential to 
cause issues if trying to administer drugs and monitor their effects simultaneously, which 
is something our lab is currently working toward. Administering drugs that are only 
powered by passive diffusion also creates a steep concentration gradient. This is an effect 
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that may be more profound with heavier drugs, but can happen with any (due to heavy 
drugs slower diffusion rates, they won’t clear from the point of origin as rapidly). We 
sought to find a solution to both of these problems with a single mechanism, and we 
believe that’s what we have done with the two-catheter system.  
 
It has become common place to use CED to deliver drugs directly into the brain or tumor; 
however, this does not allow for the simultaneous collection of metabolites during drug 
administration. We theorized that using CED simultaneously with rCED would enable us 
to control, to some extent, the diffusion of the fluid leaving the CED catheter, as well as 
provide us the ability to sample the ECF. We were able to demonstrate why using a 
micro-dialysis catheter to accomplish simultaneous collection and delivery would be 
inefficient with our relative diffusion rate experiments. What we needed, is a system that 
was not governed by parameters outside of our control, but a system which allowed us to 
control things such as diffusion rate and bulk flow, and that is how we came up with the 
CED/rCED system. In theory, this system would prevent toxic effects from drugs 
administered, distribute drugs more evenly, and allow real time analysis of the effects of 
the drugs administered.  
 
What we found in our experiments is that we were capable of doing all of these things in 
a gel phantom. By creating positive and negative pressure area in the phantom, we ended 
up with a more directed and homogenous convective flow of the fluorophore (Alexa 
Fluor 488A Amine). This experiment was run using three different pump conditions: 1-
 
33 
syringe pump at 1µL/min and roller pump at 1 µL/min. 2-syringe pump at 1µL/min and 
roller pump at 2 µL/min. 3-syringe pump at 1µL/min and roller pump at 1 µL/min. These 
variable rates were used in an attempt to magnify the influence on flow created by the 
rCED catheter. In the last CED/rCED experiment (exp. 3), what appeared to happen after 
the fluorophore reached the rCED catheter was the formation of a closed loop. The total 
fluorophore in this area was decreased despite being pumped in at the same rate as 
previous experiments. We know from the paper “Convection and Retro-Convection 
Enhanced Delivery: Some Theoretical Considerations Related to Drug Targeting” that 
fluid coming out of the CED catheter, due to its positive pressure, may have a repulsive 
effect on other molecules. In this paper, the experiment involved two parallel catheters 
under positive pressure, so it doesn’t directly translate to our experiment; however, it 
stands to reason that if the hydrostatic pressure exceeds the oncotic pressure of the 
surrounding fluid, then we should expect to see some repulsion. If other molecules in our 
closed circuit are repulsed, then the tissue being sampled will be mostly that which is 
having drug passed through it. Further studies will reveal if this theoretical closed loop 
works as we have hypothesized. All of the CED/rCED experiments thus far have been 
conducted solely with Alexa Fluor 488A Amine. Testing with some larger fluorophores 
will be the next step, this will allow us to know the extent that this system can influence 
larger molecules. 
 
Our studies also suggest that there may be some benefit in a three or four catheter system. 
For the purpose of our experiments, which are viewed on a two-dimensional plane, the 
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three-catheter system seems more viable; however, in actual brain matter, a four-catheter 
system could prove quite beneficial due to its three-dimensional nature. We believe that 
by placing the CED catheter directly in the center of a tumor and having multiple rCED 
catheters around it, we could potentially increase the effects we’ve already observed. 
What I mean by this, is that with this theoretical system we could further flatten the curve 
of drug distribution, thus creating a more even distribution of the fluorophore. We could 
also do the exact opposite of this and place an rCED catheter in the center, with two CED 
catheters on periphery. We believe that by doing this, we may be able to amplify the 
circuit that we previously created. In amplifying this circuit, we hypothesize that we 
could repel other transient molecules and sample on the tissue being treated. Another 
benefit of using three or four catheters, is that the rate of administration may be 
increased. Rapid administration may be helpful in overcoming some of the additional 
barriers that we will face when moving these experiments in vivo. 
 
While the experiments conducted may not directly translate into the brain, they have 
given us a framework to start from. Some of the additional barriers that we will face 
when we move these experiments in vitro include: efflux of drugs administered, 
metabolism of drugs administered or biomarkers being sampled, and heterogeneity within 
the tumor causing an inconsistent medium. All of these variables have potential to inhibit 
our ability to manipulate drug movement as we have with this study. We plan to slowly 
introduce more variables to these experiments to more closely mimic the brain’s true 
environment. We hope to accomplish this by testing the push-pull system in cultured 
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tumor cells. This will present us with some of the biochemical barriers that will be 
encountered in the brain; however, it will not yet account for efflux.  
 
 We believe that these advancements will soon help to accelerate the process of drug 
development for glioma by providing researchers and surgeons with a tool that allows for 
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